Muscone derivative ZM-32 inhibits breast tumor angiogenesis by suppressing HuR-mediated VEGF and MMP9 expression
Liu-Qing Yang,Shao-Peng Yu,Yan-Tao Yang,Yi-Shuang Zhao,Fei-Yun Wang,Yao Chen,Qing-Hua Li,Ping Tian,Yu-Ying Zhu,Jian-Ge Zhang,Guo-Qiang Lin,Liu-qing Yang,Shao-peng Yu,Yan-tao Yang,Yi-shuang Zhao,Fei-yun Wang,Qing-hua Li,Yu-ying Zhu,Jian-ge Zhang,Guo-qiang Lin
DOI: https://doi.org/10.1016/j.biopha.2021.111265
2021-04-01
Abstract:<p>Inhibition of tumor angiogenesis is a highly effective strategy for cancer treatment. Human antigen R (HuR), an RNA-binding protein, is overexpressed in many cancers and regulates the mRNAs of multiple angiogenic factors by binding to the adenylate-uridylate-rich element in their 3′ untranslated region. HuR protein has been demonstrated to be an important regulatory factor in macrophage-mediated angiogenesis, a process in which macrophages are critical for tumor progression. Muscone is a synthetic equivalent of musk, and recent studies have shown that it has a regulatory effect on angiogenesis. In this study, we synthesized five series of muscone derivatives and discovered that compound <strong>ZM-32</strong> was effective in preventing HuR RRM1/2-<em>Vegf-a</em> mRNA complex formation. <strong>ZM-32</strong> bound to HuR RRM1/2 protein with a <em>K</em><sub>D</sub> value of 521.7 nmol/L. Furthermore, <strong>ZM-32</strong> inhibited endothelial cell proliferation, migration, and tubule formation, and suppressed the VEGF/VEGFR2/ERK1/2 signaling axis mediated by macrophages <em>in vitro</em>. We also demonstrated that <strong>ZM-32</strong> effectively prevented the proliferation and migration of breast cancer cells and inhibited the growth and angiogenesis of MDA-MB-231 xenograft tumors without any obvious toxicity <em>in vivo</em>. Mechanistically, exposure to <strong>ZM-32</strong> influenced the mRNA stability of <em>Vegf-a</em> and <em>Mmp9</em> in a HuR-dependent manner in both macrophages and MDA-MB-231 cells. Thus, in this study we identified a new muscone derivative, <strong>ZM-32</strong>, with anti-angiogenesis effects mediated <em>via</em> targeting HuR in breast cancer, that may become a potentially valuable lead compound for anti-cancer angiogenesis.</p>
pharmacology & pharmacy,medicine, research & experimental